Dergiler / Turkish Thoracic Journal / 2019 / Cilt: 20 - Sayı: 2

The Frequency and Risk Factors for Oropharyngeal Candidiasis in Adult Asthma Patients Using Inhaled Corticosteroids

Sayfa
136–139
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further studies are needed to distinguish these individual differences.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVES: Worldwide, asthma is a major health problem and inhaled corticosteroids (ICS) are the mainstay of asthma treatment.
📊
Temel Bulgular & Veri:The present study aimed to determine the frequency of oral and systemiccandidiasis infections in adult asthma patients using ICS, and to identify possible risk factors.MATERIAL AND METHODS: This study included 186 randomly selected adult asthma patients that presented to allergy clinic betweenMay 2011 and September 2012.RESULTS: Among the patients, 147 (79%) were female.
💡
Sonuç & Katkı:Further studies are needed to distinguish these individual differences.
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

OBJECTIVES: Worldwide, asthma is a major health problem and inhaled corticosteroids (ICS) are the mainstay of asthma treatment. Highdose and long-term use of ICS can result in some side effects. The present study aimed to determine the frequency of oral and systemiccandidiasis infections in adult asthma patients using ICS, and to identify possible risk factors.MATERIAL AND METHODS: This study included 186 randomly selected adult asthma patients that presented to allergy clinic betweenMay 2011 and September 2012.RESULTS: Among the patients, 147 (79%) were female. The lifelong incidence of oral candidiasis was 19.4% (n=36), whereas 5.38%(n=10) of the patients already had it by the time of the study. The lifelong incidence of any fungal infection was 59.7% (n=111). Thereweren’t any significant differences in gender, age, age at onset of asthma, oral hygiene, atopy, or comorbid diseases between the oropharyngeal candidiasis (OPC)-positive and -negative groups. A history of persistent rhinitis, use of a leukotriene receptor antagonist togetherwith ICS, and use of ciclesonide as an ICS were associated with a higher incidence of OPC.CONCLUSION: In the present study the incidence of OPC in adult asthma patients was quite high, but no definitive risk factors wereidentified. Further studies are needed to distinguish these individual differences.

🔖

Bu Makaleye Atıf Yap

ERDOĞAN, T., KARAKAYA, G., KALYONCU, A. F. (2019). The Frequency and Risk Factors for Oropharyngeal Candidiasis in Adult Asthma Patients Using Inhaled Corticosteroids. Turkish Thoracic Journal, Cilt: 20 - Sayı: 2, 136–139. https://ajindex.com/articles/418026

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Global Initiative for Asthma Guideline 2015
  2. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999;159:941-55. [CrossRef] 3. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469-78. [CrossRef] 4. Godara N, Godara R, Khullar M. Impact of inhalation therapy on oral health. Lung India 2011;28:272-5. [CrossRef] 5. Fukushima C, Matsuse H, Tomari S, et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of flu- ticasone and beclomethasone. Ann Allergy Asthma Immunol 2003;90:646-51. [CrossRef] 6. Craig T. The safety profile of ciclesonide in treatment of per- sistent asthma. Allergy Asthma Proc 2009;30:315-24. [CrossRef] 7. Roland JN, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126:213-9. [CrossRef] 8. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518-26. [CrossRef] 9. Barnes PJ, Pederson S, Busse WW. Efficacy and safety of inhaled corticosteroids; new developments. Am J Resp Crit Care Med 1998;157:1-53. [CrossRef] 10. Woodcock A, Lötvall J, Busse WW et al. Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24- week randomised study. BMC Pulm Med 2014;14:113. [CrossRef] 11. Bernstein DI, Bateman ED, Woodcock A et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma 2015;52:1073-83. [CrossRef] 12. Kennedy WA, Laurier C, Gautrin D et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. J Clin Epidemiol 2000;53:696-701. [CrossRef] 13. Asthma Diagnosis and Treatment Guideline 2014, Turkish Thoracic Society
  3. Pinto CR, Almeida NR, Marques TS et al. Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma. J Bras Pneumol 2013;39:409- 17 [CrossRef]